A Phase 2 interventional study of Buspirone Hydrochloride and Buspirone placebo in Spinal Cord Injuries, sponsored by Spaulding Rehabilitation Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Spaulding Rehabilitation Hospital · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital — 3 open to participants now, 8 under way, none of them phase 3. Spinal Cord Injuries · Spaulding Rehabilitation Hospital.
Among the 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2020, is one of 3 in phase 2, and was the 16th registered.
2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.
Browse Spinal Cord Injuries studies →3 of the 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital are open now, in 1 country. Recruiting first, the newest first:
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–80
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–60
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–75 · Healthy volunteers
By country, each count listing its studies:
Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4
First in 2010; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 24 across 1,639 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 24 across the 25 interventional studies. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
Spaulding Rehabilitation Hospital is the lead sponsor of 118 studies on the registry; 27 are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 17 (85%) have results posted.
4 of the studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06514950Spaulding Rehabilitation HospitalYoga Breath Training to Improve Cardiorespiratory Synchrony in Spinal Cord Injury | 2027-01-01 |
| NCT02274116Spaulding Rehabilitation HospitalAcute Intermittent Hypoxia on Leg Function Following Spinal Cord Injury | 2027-08 |
| NCT02323945Spaulding Rehabilitation HospitalEffects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury | 2027-08 |
| NCT06521723Spaulding Rehabilitation HospitalLow Oxygen Therapy to Enhance Walking Recovery After SCI. | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Over the past ten years, the Cardiovascular Research Laboratory at Spaulding has refined a unique form of exercise for those with spinal cord injuries (SCI). Functional Electrical Stimulation Row Training (FESRT) couples volitional arm and electrically controlled leg exercise, resulting in the benefits of large muscle mass exercise. However, despite the potential for enhancing aerobic capacity by training the denervated leg skeletal muscle via hybrid FES exercise, the inability to increase ventilation beyond limits set by high level SCI restricts aerobic capacity.
This research study will investigate two potential methods of improving ventilation in those with high-level SCI through a double-blind randomized trial. One method is non-invasive ventilation (NIV), which is an external breathing support machine. The second method is the use of Buspar, a drug, which has been used to treat respiratory dysfunction after SCI in rats and some human case reports.
In this study, participants will engage in a 6-month FES row training program while receiving either NIV or shamNIV and Buspar or placebo, and under study tests to evaluate cardiopulmonary health and fitness.
Regular aerobic exercise with sufficient intensity can improve overall health, however daily energy expenditure is low in those with SCI, especially in those with high level lesions. The investigators have developed Functional Electrical Stimulation Row Training (FESRT) that couples volitional arm and electrically controlled leg exercise, increasing the active muscle and resulting in benefits of large muscle mass exercise. Despite the potential for enhancing aerobic capacity, those with high level lesions (T3 and above) have a remaining obstacle to attaining higher work capacities: a level of pulmonary muscle denervation. The investigators preliminary work suggests this limits the aerobic capacity that can be achieved with FESRT.
External ventilatory support could improve the ability to exercise train and hence enhance the adaptations to chronic exercise in high level SCI. Non invasive ventilation (NIV) during exercise training has been shown to improve gains in exercise capacity in those with similarly restrictive breathing. Therefore, the investigators hypothesize that the use of NIV during FESRT will reduce ventilatory limits to exercise, leading to increased aerobic capacity in high level SCI. In addition, pharmacologic treatments may augment respiratory control and improve exercise ventilatory responses. Buspirone can reverse respiratory abnormalities consequent to SCI in rats, and humans case reports suggest successful Buspirone treatment of respiratory dysfunction
Therefore, the investigators propose a double-blind 2x2 trial of 6 months of FESRT with NIV or Sham and Buspirone or Placebo in individuals with acute, high-level SCI. The investigators hypothesize that both NIV and Buspirone will improve ventilatory exercise responses and that combined treatment will have the greatest effect. This will result in greater improvements in aerobic capacity and concomitant increases in pulmonary function and reductions in cardiometabolic risk. This work proposes two approaches to overcome ventilatory limitations to exercise in high level SCI and allow for greater improvements in cardiopulmonary capacity - one that overcomes mechanical limitations of paralyzed pulmonary musculature and one that treats loss of serotonergic respiratory control, both of which may contribute to blunted ventilatory responses. The ultimate purpose of this research is to optimize exercise for a population that both needs and seeks the broad range of benefits that exercise can confer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will perform 6 months of FES-row-training while receiving NIV and taking Buspar.
Drug: Buspirone Hydrochloride · Device: Noninvasive Ventilation (NIV) · Other: Functional Electrical Stimulation Row Training (FESRT)
Subjects will perform 6 months of FES-row-training while receiving NIV and taking placebo.
Drug: Buspirone placebo · Device: Noninvasive Ventilation (NIV) · Other: Functional Electrical Stimulation Row Training (FESRT)
Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking Buspar.
Drug: Buspirone Hydrochloride · Device: Sham Non-invasive ventilation (NIV) · Other: Functional Electrical Stimulation Row Training (FESRT)
Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking placebo.
Drug: Buspirone placebo · Device: Sham Non-invasive ventilation (NIV) · Other: Functional Electrical Stimulation Row Training (FESRT)
Subjects take 30 mg buspirone HCl twice a day for 6 months.
Also known as: Buspar
Subjects take a placebo tablet twice a day for 6 months.
The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
Change in baseline aerobic exercise capacity
Participants perform incremental FES rowing exercise test to determine maximum oxygen consumption (VO2 peak)
Time frame: Baseline, 3 months, 6 months
Change in baseline ventilation during exercise
Participants perform incremental FES rowing exercise test to determine ventilation during exercise (VE peak).
Time frame: Baseline, 3 months, 6 months
Change from baseline in glucoregulatory status
Blood will be taken via standard venipuncture to measure the homeostasis model assessment (HOMA) of insulin resistance.
Time frame: Baseline, 3 months, 6 months
Change from baseline in glucoregulatory status
Blood will be taken via standard venipuncture to measure the quantitative insulin check index (QUICKI).
Time frame: Baseline, 3 months, 6 months
Change from baseline in glucoregulatory status
Blood will be taken via standard venipuncture to measure hemoglobin A1c.
Time frame: Baseline, 3 months, 6 months
Change from baseline in serum lipids
Blood will be taken via standard venipuncture to measure plasma total cholesterol.
Time frame: Baseline, 3 months, 6 months
Change from baseline in serum lipids
Blood will be taken via standard venipuncture to measure low-density lipoprotein cholesterol.
Time frame: Baseline, 3 months, 6 months
Change from baseline in serum lipids
Blood will be taken via standard venipuncture to measure high density apolipoprotein cholesterol.
Time frame: Baseline, 3 months, 6 months
Change from baseline in serum lipids
Blood will be taken via standard venipuncture to measure triglycerides.
Time frame: Baseline, 3 months, 6 months
Change from baseline in visceral adiposity
The investigators will use a 5th generation General Electric Healthcare dual x-ray absorptiometry (DXA) scanner for regional fat measurements, the DXA software can be used to define standard regions that will allow comparability of measurements throughout the study.
Time frame: Baseline, 3 months, 6 months
Change in baseline forced vital capacity
Spirometry will be used to measure lung function, specifically forced vital capacity (FVC).
Time frame: Baseline, 3 months, 6 months
Change in baseline maximal voluntary ventilation
Spirometry will be used to measure lung function, specifically maximal voluntary ventilation (MVV).
Time frame: Baseline, 3 months, 6 months
Change in baseline forced expiratory capacity in the first second
Spirometry will be used to measure lung function, specifically forced expiratory capacity in the first second (FEV1).
Time frame: Baseline, 3 months, 6 months
Ran from Dec 2020 to primary completion in Apr 2026, 63 months.
Of 44 non-industry phase 2 interventional studies under Spinal Cord Injuries, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 64. This study's 63 months is above that.
Counting every sponsor, half of 49 studies reached it within 46 months; a quarter within 28 and three quarters within 64.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jul 2026 → Apr 2026 and completion Jul 2027 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Buspirone
Spaulding Rehabilitation Hospital →